Insider Trading & Ownership of Edward T. Mathers

Location
New York, NY
Summary
The estimated net worth of Edward T. Mathers is at least $355,573,085 dollars as of 05 Feb 2026. Edward T. Mathers is the 10%+ Owner of Monte Rosa Therapeutics, Inc. and owns shares of Monte Rosa Therapeutics, Inc. (GLUE) stock worth about $146.15M. Edward T. Mathers is the 10%+ Owner of Savara Inc and owns shares of Savara Inc (SVRA) stock worth about $108.9M. Edward T. Mathers is the 10%+ Owner of Korro Bio, Inc. and owns shares of Korro Bio, Inc. (KRRO) stock worth about $61.08M. Edward T. Mathers is the Director, 10%+ Owner of MBX Biosciences, Inc. and owns shares of MBX Biosciences, Inc. (MBX) stock worth about $38.64M. Edward T. Mathers is the Director of RHYTHM PHARMACEUTICALS, INC. and owns shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) stock worth about $753.1K. Edward T. Mathers is the Director of OnKure Therapeutics, Inc. and owns shares of OnKure Therapeutics, Inc. (OKUR) stock worth about $45.9K.
Signature
/s/ Zachary Bambach, attorney-in-fact
All Insider Reports
All Insider Reports

Notify me when Edward T. Mathers files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of Edward T. Mathers

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
GLUE Monte Rosa Therapeutics, Inc. 10%+ Owner $146,153,662 28 Jun 2021
SVRA Savara Inc 10%+ Owner $108,897,125 17 Jul 2023
KRRO Korro Bio, Inc. 10%+ Owner $61,084,408 22 Apr 2024
MBX MBX Biosciences, Inc. Director, 10%+ Owner $38,638,855 05 Jun 2025
RYTM RHYTHM PHARMACEUTICALS, INC. Director $753,105 24 Jun 2025
OKUR OnKure Therapeutics, Inc. Director $45,930 31 Dec 2025
NEUE NeueHealth, Inc. Director, 10%+ Owner $0 -$24,536 -100% 02 Oct 2025
AKUS Akouos, Inc. Director 01 Dec 2022
INZY Inozyme Pharma, Inc. Director 18 Jun 2024
MIRM Mirum Pharmaceuticals, Inc. Director 02 Jun 2022
OBSV ObsEva SA Director 01 Jan 2023
SNTI Senti Biosciences, Inc. Director 25 Jun 2025
SGP SpyGlass Pharma, Inc. 10%+ Owner 05 Feb 2026
SYBX SYNLOGIC, INC. Director 22 Jun 2023
TRVI Trevi Therapeutics, Inc. Director 11 Jun 2025

Insider Transactions Reported by Edward T. Mathers:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.